Lv2
188 积分 2025-05-30 加入
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
1个月前
已完结
Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal–gastric varices
1个月前
已完结
Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab
1个月前
已完结
Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: A systematic review and meta‐analysis of recent randomized controlled trials
1个月前
已完结
Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial
2个月前
已完结
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)
4个月前
已完结
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma
6个月前
已关闭
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis
7个月前
已完结
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
7个月前
已完结
Association of care fragmentation and hospital cancer designation with survival in gastroesophageal junction cancer: a statewide study
7个月前
已关闭
皖公网安备34019202002308
